#USA #Chicago #Bantam Pharmaceutical #BTM-3566 #AACR Annual Meeting

Bantam Pharmaceutical to Present at the AACR Annual Meeting 2025

Bantam Pharmaceutical, a pioneering company in drug discovery and development focusing on cancer treatment through mitochondrial dynamics, is set to make a significant impression at the upcoming American Association for Cancer Research (AACR) Annual Meeting scheduled for April 25-30, 2025, in Chicago, Illinois. The company will present essential findings regarding their lead drug candidate, BTM-3566, which has shown promise in fighting aggressive tumors with challenging profiles.

Highlights of Bantam Pharmaceutical's Presentation

The centerpiece of Bantam's presentation will be a poster that showcases impressive data related to tumor regression. BTM-3566 is classified as a first-in-class small molecule therapeutic that specifically targets aggressive tumors that have resisted traditional treatment methods. The unique mechanism of action involves leveraging the OMA1-ATF4 Integrated Stress Response (ISR)—a newly identified pathway crucial in maintaining mitochondrial function.

Clinical data reveal that BTM-3566 exhibits notable efficacy as a standalone treatment in in vivo models of solid tumors, particularly those with low FAM210B RNA expression levels. The ongoing preclinical trials suggest that combining BTM-3566 with BH3 mimetics could enhance its effectiveness, especially in those tumors that have proved difficult to treat historically.

Presentation Details

• - Title: Selective Pharmacological Activation of the Mitochondrial Protease OMA1 Inhibits Tumor Growth and Induces Regression in Tumors Expressing Low Levels of FAM210B
• - Presenter: Matthew Kostura, PhD, Chief Scientific Officer, Bantam Pharmaceutical
• - Session: Experimental and Molecular Therapeutics
• - Date/Time: Monday, April 28th, from 3 p.m. to 6 p.m. ET
• - Abstract Number: 3032

In addition to the insightful poster that Bantam plans to showcase, the company will make related materials available on their website following the event. This engaging presentation at AACR emerges as a critical moment to address the pressing challenges in oncology, offering hope to patients with few other treatment avenues.

About BTM-3566

BTM-3566 is designed to be an orally administered small molecule targeting a broad spectrum of cancers, including hematological malignancies such as mature B-cell lymphomas—namely, mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). Early studies indicate that BTM-3566 effectively drives significant regression of tumors, showing the potential for complete elimination in cases identified as resistant to conventional therapies, including CAR-T cell therapy. The drug's mechanism induces apoptosis in tumor cells by disrupting their mitochondrial functions, leading to natural cell death.

Presently, BTM-3566 is undergoing a Phase 1 clinical trial across the U.S. and Canada for patients suffering from relapsed or refractory mature B-cell lymphomas. Those interested in details about the U.S. trial can view it on ClinicalTrials.gov by searching for NCT06792734.

Company Overview

Bantam Pharmaceutical is at the cutting edge of drug discovery and development, utilizing the intricacies of mitochondrial dynamics to deliver innovative solutions that address significant healthcare challenges in oncology. By focusing on first-in-class oral small molecule therapies, Bantam targets difficult-to-treat hematological and solid tumors. The company holds an active Investigational New Drug (IND) application in the U.S. as well as a Clinical Trial Application (CTA) in Canada for BTM-3566, demonstrating its commitment to advancing clinical development aimed at providing critical treatment options for patients in need.

For further details on Bantam Pharmaceutical and its promising drug candidate, visit Bantam Pharmaceutical's website.